(2R)-N-[(2R)-1-[[(2R)-1-[[(Z)-1-[[(3S,6S,12R,15R,16S)-3-(4-aminobutyl)-6-(2-aminoethyl)-12-[(2R)-butan-2-yl]-16-methyl-2,5,8,11,14-pentaoxo-1-oxa-4,7,10,13-tetrazacyclohexadec-15-yl]amino]-1-oxobut-2-en-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2S)-3-hydroxy-2-[[(2R)-2-[[(2S)-2-[[(2R)-3-hydroxy-2-[[(2R)-1-[(Z)-2-[[(3S)-3-hydroxyoctanoyl]amino]but-2-enoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]pentanediamide
| Internal ID | 9dd61a06-2f6a-4358-87ca-e4825d5d66a7 |
| Taxonomy | Organic acids and derivatives > Peptidomimetics > Depsipeptides > Cyclic depsipeptides |
| IUPAC Name | (2R)-N-[(2R)-1-[[(2R)-1-[[(Z)-1-[[(3S,6S,12R,15R,16S)-3-(4-aminobutyl)-6-(2-aminoethyl)-12-[(2R)-butan-2-yl]-16-methyl-2,5,8,11,14-pentaoxo-1-oxa-4,7,10,13-tetrazacyclohexadec-15-yl]amino]-1-oxobut-2-en-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2S)-3-hydroxy-2-[[(2R)-2-[[(2S)-2-[[(2R)-3-hydroxy-2-[[(2R)-1-[(Z)-2-[[(3S)-3-hydroxyoctanoyl]amino]but-2-enoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]pentanediamide |
| SMILES (Canonical) | CCCCCC(CC(=O)NC(=CC)C(=O)N1CCCC1C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(=CC)C(=O)NC2C(OC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC2=O)C(C)CC)CCN)CCCCN)C)O |
| SMILES (Isomeric) | CCCCC[C@@H](CC(=O)N/C(=C\C)/C(=O)N1CCC[C@@H]1C(=O)N[C@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(=O)N)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](C(C)C)C(=O)N/C(=C\C)/C(=O)N[C@@H]2[C@@H](OC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](NC2=O)[C@H](C)CC)CCN)CCCCN)C)O |
| InChI | InChI=1S/C92H159N21O24/c1-21-25-26-30-55(116)42-68(118)97-57(24-4)91(135)113-38-29-32-66(113)84(128)105-64(44-114)82(126)103-62(40-47(7)8)80(124)108-71(50(13)14)88(132)106-65(45-115)83(127)104-63(41-48(9)10)81(125)109-73(52(17)18)89(133)110-72(51(15)16)87(131)100-58(33-34-67(95)117)77(121)102-61(39-46(5)6)79(123)107-70(49(11)12)86(130)99-56(23-3)76(120)112-75-54(20)137-92(136)60(31-27-28-36-93)101-78(122)59(35-37-94)98-69(119)43-96-85(129)74(53(19)22-2)111-90(75)134/h23-24,46-55,58-66,70-75,114-116H,21-22,25-45,93-94H2,1-20H3,(H2,95,117)(H,96,129)(H,97,118)(H,98,119)(H,99,130)(H,100,131)(H,101,122)(H,102,121)(H,103,126)(H,104,127)(H,105,128)(H,106,132)(H,107,123)(H,108,124)(H,109,125)(H,110,133)(H,111,134)(H,112,120)/b56-23-,57-24-/t53-,54+,55+,58-,59+,60+,61-,62+,63-,64-,65+,66-,70-,71-,72-,73-,74-,75-/m1/s1 |
| InChI Key | WIHRLQAWWRZRCA-VFRMFFLVSA-N |
| Popularity | 1 reference in papers |
| Molecular Formula | C92H159N21O24 |
| Molecular Weight | 1943.40 g/mol |
| Exact Mass | 1942.18668502 g/mol |
| Topological Polar Surface Area (TPSA) | 697.00 Ų |
| XlogP | 2.60 |
| Atomic LogP (AlogP) | -3.27 |
| H-Bond Acceptor | 26 |
| H-Bond Donor | 23 |
| Rotatable Bonds | 55 |
| There are no found synonyms. |
| Target | Value | Probability (raw) | Probability (%) |
|---|---|---|---|
| Human Intestinal Absorption | + | 0.6269 | 62.69% |
| Caco-2 | - | 0.8584 | 85.84% |
| Blood Brain Barrier | - | 0.9000 | 90.00% |
| Human oral bioavailability | - | 0.6286 | 62.86% |
| Subcellular localzation | Lysosomes | 0.5413 | 54.13% |
| OATP2B1 inhibitior | - | 1.0000 | 100.00% |
| OATP1B1 inhibitior | + | 0.8093 | 80.93% |
| OATP1B3 inhibitior | + | 0.9099 | 90.99% |
| MATE1 inhibitior | - | 0.9412 | 94.12% |
| OCT2 inhibitior | - | 0.9750 | 97.50% |
| BSEP inhibitior | + | 0.9794 | 97.94% |
| P-glycoprotein inhibitior | + | 0.7418 | 74.18% |
| P-glycoprotein substrate | + | 0.8830 | 88.30% |
| CYP3A4 substrate | + | 0.7529 | 75.29% |
| CYP2C9 substrate | - | 1.0000 | 100.00% |
| CYP2D6 substrate | - | 0.8458 | 84.58% |
| CYP3A4 inhibition | - | 0.8100 | 81.00% |
| CYP2C9 inhibition | - | 0.8847 | 88.47% |
| CYP2C19 inhibition | - | 0.8808 | 88.08% |
| CYP2D6 inhibition | - | 0.9198 | 91.98% |
| CYP1A2 inhibition | - | 0.8974 | 89.74% |
| CYP2C8 inhibition | + | 0.8069 | 80.69% |
| CYP inhibitory promiscuity | - | 0.9748 | 97.48% |
| UGT catelyzed | + | 0.7000 | 70.00% |
| Carcinogenicity (binary) | - | 0.8500 | 85.00% |
| Carcinogenicity (trinary) | Non-required | 0.5250 | 52.50% |
| Eye corrosion | - | 0.9837 | 98.37% |
| Eye irritation | - | 0.8954 | 89.54% |
| Skin irritation | - | 0.7594 | 75.94% |
| Skin corrosion | - | 0.9049 | 90.49% |
| Ames mutagenesis | - | 0.6200 | 62.00% |
| Human Ether-a-go-go-Related Gene inhibition | + | 0.7168 | 71.68% |
| Micronuclear | + | 0.8200 | 82.00% |
| Hepatotoxicity | - | 0.5864 | 58.64% |
| skin sensitisation | - | 0.8525 | 85.25% |
| Respiratory toxicity | + | 0.7667 | 76.67% |
| Reproductive toxicity | + | 0.8333 | 83.33% |
| Mitochondrial toxicity | + | 0.8125 | 81.25% |
| Nephrotoxicity | + | 0.8718 | 87.18% |
| Acute Oral Toxicity (c) | III | 0.6155 | 61.55% |
| Estrogen receptor binding | - | 0.4748 | 47.48% |
| Androgen receptor binding | + | 0.7382 | 73.82% |
| Thyroid receptor binding | + | 0.7236 | 72.36% |
| Glucocorticoid receptor binding | + | 0.8055 | 80.55% |
| Aromatase binding | + | 0.8054 | 80.54% |
| PPAR gamma | + | 0.7803 | 78.03% |
| Honey bee toxicity | - | 0.6556 | 65.56% |
| Biodegradation | - | 0.7500 | 75.00% |
| Crustacea aquatic toxicity | + | 0.5100 | 51.00% |
| Fish aquatic toxicity | + | 0.8374 | 83.74% |
Proven Targets:
| CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
|---|---|---|---|---|---|
| No proven targets yet! | |||||
Predicted Targets (via Super-PRED):
| CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
|---|---|---|---|---|
| CHEMBL3837 | P07711 | Cathepsin L | 99.96% | 96.61% |
| CHEMBL2581 | P07339 | Cathepsin D | 99.84% | 98.95% |
| CHEMBL2107 | P61073 | C-X-C chemokine receptor type 4 | 98.92% | 93.10% |
| CHEMBL4588 | P22894 | Matrix metalloproteinase 8 | 98.90% | 94.66% |
| CHEMBL2730 | P21980 | Protein-glutamine gamma-glutamyltransferase | 98.89% | 92.38% |
| CHEMBL4801 | P29466 | Caspase-1 | 98.79% | 96.85% |
| CHEMBL253 | P34972 | Cannabinoid CB2 receptor | 98.69% | 97.25% |
| CHEMBL1801 | P00747 | Plasminogen | 98.54% | 92.44% |
| CHEMBL2208 | P49137 | MAP kinase-activated protein kinase 2 | 98.52% | 95.20% |
| CHEMBL1795139 | Q8IU80 | Transmembrane protease serine 6 | 98.48% | 98.33% |
| CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 98.28% | 96.09% |
| CHEMBL2094135 | Q96BI3 | Gamma-secretase | 98.08% | 98.05% |
| CHEMBL4296 | Q15858 | Sodium channel protein type IX alpha subunit | 97.86% | 96.11% |
| CHEMBL3137262 | O60341 | LSD1/CoREST complex | 97.64% | 97.09% |
| CHEMBL230 | P35354 | Cyclooxygenase-2 | 97.43% | 89.63% |
| CHEMBL2693 | Q9UIQ6 | Cystinyl aminopeptidase | 97.17% | 97.64% |
| CHEMBL3359 | P21462 | Formyl peptide receptor 1 | 97.15% | 93.56% |
| CHEMBL2514 | O95665 | Neurotensin receptor 2 | 97.01% | 100.00% |
| CHEMBL237 | P41145 | Kappa opioid receptor | 96.97% | 98.10% |
| CHEMBL3130 | O00329 | PI3-kinase p110-delta subunit | 96.68% | 96.47% |
| CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 96.28% | 91.11% |
| CHEMBL4018 | P49146 | Neuropeptide Y receptor type 2 | 96.26% | 98.94% |
| CHEMBL2492 | P36544 | Neuronal acetylcholine receptor protein alpha-7 subunit | 96.03% | 88.42% |
| CHEMBL5043 | Q6P179 | Endoplasmic reticulum aminopeptidase 2 | 95.95% | 91.81% |
| CHEMBL3468 | P55210 | Caspase-7 | 95.80% | 95.68% |
| CHEMBL3060 | Q9Y345 | Glycine transporter 2 | 95.69% | 99.17% |
| CHEMBL4187 | Q99250 | Sodium channel protein type II alpha subunit | 95.68% | 95.50% |
| CHEMBL4478 | Q00975 | Voltage-gated N-type calcium channel alpha-1B subunit | 95.58% | 97.14% |
| CHEMBL5103 | Q969S8 | Histone deacetylase 10 | 95.45% | 90.08% |
| CHEMBL3024 | P53350 | Serine/threonine-protein kinase PLK1 | 95.24% | 97.43% |
| CHEMBL1944495 | P28065 | Proteasome subunit beta type-9 | 95.00% | 97.50% |
| CHEMBL4462 | Q8IXJ6 | NAD-dependent deacetylase sirtuin 2 | 94.48% | 90.24% |
| CHEMBL2069156 | Q14145 | Kelch-like ECH-associated protein 1 | 94.29% | 82.38% |
| CHEMBL5163 | Q9NY46 | Sodium channel protein type III alpha subunit | 93.68% | 96.90% |
| CHEMBL3145 | P42338 | PI3-kinase p110-beta subunit | 93.64% | 98.75% |
| CHEMBL3176 | O43603 | Galanin receptor 2 | 92.78% | 98.89% |
| CHEMBL2955 | O95136 | Sphingosine 1-phosphate receptor Edg-5 | 92.76% | 92.86% |
| CHEMBL221 | P23219 | Cyclooxygenase-1 | 92.70% | 90.17% |
| CHEMBL4227 | P25090 | Lipoxin A4 receptor | 92.59% | 100.00% |
| CHEMBL4581 | P52732 | Kinesin-like protein 1 | 92.28% | 93.18% |
| CHEMBL4123 | P30989 | Neurotensin receptor 1 | 92.21% | 96.67% |
| CHEMBL3807 | P17706 | T-cell protein-tyrosine phosphatase | 91.80% | 93.00% |
| CHEMBL259 | P32245 | Melanocortin receptor 4 | 91.58% | 95.38% |
| CHEMBL2274 | Q9H228 | Sphingosine 1-phosphate receptor Edg-8 | 91.50% | 100.00% |
| CHEMBL3392948 | Q9NP59 | Solute carrier family 40 member 1 | 91.49% | 95.00% |
| CHEMBL5845 | P23415 | Glycine receptor subunit alpha-1 | 91.35% | 90.71% |
| CHEMBL4979 | P13866 | Sodium/glucose cotransporter 1 | 91.11% | 98.24% |
| CHEMBL236 | P41143 | Delta opioid receptor | 89.99% | 99.35% |
| CHEMBL3310 | Q96DB2 | Histone deacetylase 11 | 89.93% | 88.56% |
| CHEMBL332 | P03956 | Matrix metalloproteinase-1 | 89.75% | 94.50% |
| CHEMBL340 | P08684 | Cytochrome P450 3A4 | 89.61% | 91.19% |
| CHEMBL1907591 | P30926 | Neuronal acetylcholine receptor; alpha4/beta4 | 89.38% | 100.00% |
| CHEMBL321 | P14780 | Matrix metalloproteinase 9 | 89.37% | 92.12% |
| CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 89.16% | 94.45% |
| CHEMBL2072 | P35499 | Sodium channel protein type IV alpha subunit | 89.02% | 92.32% |
| CHEMBL4071 | P08311 | Cathepsin G | 88.66% | 94.64% |
| CHEMBL2111367 | P27986 | PI3-kinase p110-alpha/p85-alpha | 88.49% | 94.33% |
| CHEMBL4481 | P35228 | Nitric oxide synthase, inducible | 88.29% | 94.80% |
| CHEMBL4026 | P40763 | Signal transducer and activator of transcription 3 | 88.19% | 82.69% |
| CHEMBL3892 | Q99500 | Sphingosine 1-phosphate receptor Edg-3 | 87.89% | 97.29% |
| CHEMBL333 | P08253 | Matrix metalloproteinase-2 | 87.22% | 96.31% |
| CHEMBL3108638 | O15164 | Transcription intermediary factor 1-alpha | 87.00% | 95.56% |
| CHEMBL255 | P29275 | Adenosine A2b receptor | 86.61% | 98.59% |
| CHEMBL3267 | P48736 | PI3-kinase p110-gamma subunit | 86.01% | 95.71% |
| CHEMBL3476 | O15111 | Inhibitor of nuclear factor kappa B kinase alpha subunit | 85.87% | 95.83% |
| CHEMBL4625 | Q07817 | Apoptosis regulator Bcl-X | 85.48% | 99.77% |
| CHEMBL1907600 | Q00535 | Cyclin-dependent kinase 5/CDK5 activator 1 | 85.07% | 93.03% |
| CHEMBL2781 | P19634 | Sodium/hydrogen exchanger 1 | 84.90% | 90.24% |
| CHEMBL299 | P17252 | Protein kinase C alpha | 84.74% | 98.03% |
| CHEMBL1907589 | P17787 | Neuronal acetylcholine receptor; alpha4/beta2 | 84.70% | 94.55% |
| CHEMBL283 | P08254 | Matrix metalloproteinase 3 | 84.50% | 97.29% |
| CHEMBL1907602 | P06493 | Cyclin-dependent kinase 1/cyclin B1 | 83.98% | 91.24% |
| CHEMBL1907605 | P24864 | Cyclin-dependent kinase 2/cyclin E1 | 83.78% | 92.88% |
| CHEMBL5608 | Q16288 | NT-3 growth factor receptor | 83.77% | 95.89% |
| CHEMBL4374 | Q9Y5X4 | Photoreceptor-specific nuclear receptor | 83.74% | 85.00% |
| CHEMBL2001 | Q9H244 | Purinergic receptor P2Y12 | 83.70% | 96.00% |
| CHEMBL2073 | P07947 | Tyrosine-protein kinase YES | 83.67% | 83.14% |
| CHEMBL1075317 | P61964 | WD repeat-containing protein 5 | 83.50% | 96.33% |
| CHEMBL4777 | P25929 | Neuropeptide Y receptor type 1 | 82.81% | 96.67% |
| CHEMBL5500 | Q92831 | Histone acetyltransferase PCAF | 82.51% | 91.96% |
| CHEMBL1994 | P08235 | Mineralocorticoid receptor | 82.13% | 100.00% |
| CHEMBL325 | Q13547 | Histone deacetylase 1 | 81.93% | 95.92% |
| CHEMBL3038469 | P24941 | CDK2/Cyclin A | 81.75% | 91.38% |
| CHEMBL4005 | P42336 | PI3-kinase p110-alpha subunit | 80.92% | 97.47% |
| CHEMBL5469 | Q14289 | Protein tyrosine kinase 2 beta | 80.88% | 91.03% |
| CHEMBL3038477 | P67870 | Casein kinase II alpha/beta | 80.51% | 99.23% |
| CHEMBL3880 | P07900 | Heat shock protein HSP 90-alpha | 80.10% | 96.21% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
| There are no matching plants. |
| PubChem | 163056310 |
| LOTUS | LTS0110381 |
| wikiData | Q105306238 |